Headline data expected Q2 2016; US clinical development plans on track Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces enrolment of the first ten US patients in the Company’s GrassMATAMPL 204 phase II study . G204 is a double-blind, placebo-controlled cumulative dose selection study for grass allergic rhinitis, which follows the successful completion of the GMM102 safety study, which demonstrated safety of two new doses of GMM and supports the further testing of efficacy in the current G204 study.